About Us
Cardiovascular diseases are the leading cause of mortality globally, responsible for 18 million deaths per year.
Cardiovascular Diagnosis and prognosis estimation today remain a challenge. Estimates are often inaccurate, time-consuming and many times invasive. General practitioners may fail to recognise the presence of increased risk of suffering a major cardiovascular event. Late diagnosis and inadequate prognosis decreases the chances for successful interventions creating financial and psychological strain for the patient, their families and their doctors. Cardiovascular science still trusts single biochemical markers such as cholesterol, but in the twenty-first century it is possible to know much more about the many alterations leading to atherosclerosis.
We want to change this by making routine and frequent screening for cardiovascular diseases possible for anyone on earth.
We offer a whole blood screening test using RNA Sequencing and Artificial Intelligence to detect virtually any complex diseases, including cardiovascular disorders and cancer.
Rather than searching for a single molecule that identifies a cardiovascular risk, our test identifies molecular variances in the blood that indicate an increased risk of a cardiovascular event. Imagine measuring all blood RNA changes that a cardiac risk factor may induce at the same time: A powerful, deep and accurate superbiomarker.
This gives MultiplAI the power to:
- Offer a whole blood liquid biopsy screening test for cardiovascular diseases and other complex diseases.
- Reliably achieve high diagnostic accuracy
- Provide screening at a fraction of the cost of existing diagnosis options
- Predict prognosis and evaluate treatment results
- Administer testing anywhere you can safely extract a blood sample
Timing is Everything
MultiplAI brings together maturing artificial intelligence algorithms, cost-effective sequencing and remote medicine to detect cardiovascular and other complex diseases and better establish prognosis based on the biological substrate.
It’s time to imagine modern universal remote screening for cardiovascular diseases.
Introducing the
MultiplAI superbiomarker
With advances in RNA sequencing, bioinformatic processing and deep learning, we now have the power to measure many biomarkers in the blood.
Our patented RNAseq data transformation process makes it possible to represent the incredible complexity of RNA in highly efficient formats ideal for algorithmic analysis.
The Team
Santiago Miriuka (MD, PhD)
Santiago Miriuka (MD, PhD)
Santiago Miriuka (MD, PhD)
Medical Doctor with 20+ years in clinical cardiology. Director of a lab of postdocs with 60+ publications working on cutting-edge cellular and molecular biology. Data scientist and coder looking forward to innovating in medicine.
Carlos Luzzani (PhD)
Santiago Miriuka (MD, PhD)
Santiago Miriuka (MD, PhD)
Molecular biologist and biotech specialist with experience co-founding a bioprinting startup (WeBio). Investigator at FLENI-CONICET with 20 peer-reviewed publications.
Mark Paul Ramondt (MBA)
Santiago Miriuka (MD, PhD)
Mark Paul Ramondt (MBA)
Serial entrepreneur, angel investor and advisor to startups with 25+ years of corporate finance and open innovation experience.
Advisors
.jpg/:/rs=w:365,h:365,cg:true,m/cr=w:365,h:365/fx-gs/qt=q:1)
Nir Ayalon (PhD candidate)
Nir Ayalon (PhD candidate)
Nir Ayalon (PhD candidate)
Tel Aviv, Israel
Serial entrepreneur and computer scientist with contacts in Europe and Israel, and expertise in data science, engineering and data privacy.
Carl Cook (PhD)
Nir Ayalon (PhD candidate)
Nir Ayalon (PhD candidate)
Cambridge, MA, USA
Senior pharmaceutical executive based in Boston with 20+ years of experience in clinical oncology and precision medicine.